TheraCell-VET is the veterinary products division of TheraCell. The company is dedicated to bringing the advantages of TheraCell’s Demineralized Bone Fiber (DBF™) Technology and product pipeline to the veterinary market. Our flagship product VET Fiber Matrix™ is the only veterinary bone grafting product that offers the benefits of DBF™ including enhanced bone healing performance due to its osteoinductive and exceptional osteoconductive properties, ease of use intraoperatively, avoidance of migration from the graft site, all in a natural, additive free product.
TheraCell was founded in 2008 to exploit technology developed at the Hebrew University by leading researcher Dan Gazit, PhD and his team. The technology included a stem cell sorting device to concentrate mesenchymal stem cells from adipose tissue and Oxygenation technology to improve survival of stem cell preparations.
Guided by a team of influential spine surgeons, and led by experienced Medical Device executives, TheraCell has further developed methodologies and gained patent protection for applying the oxygenation technology to demineralized bone matrix (DBM) and Demineralized Bone Fiber (DBF™) products. We have also developed a proprietary, patent pending process for the production of Demineralized Bone Fibers. Our DBF™ technology has allowed the development of a number of Fiber Matrix™ products and a strong pipeline of future products. We also have a proprietary, patent pending process to enhance the osteoinductivity of demineralized cancellous bone, a popular bone graft option used in human and veterinary procedures.
TheraCell established an R&D laboratory in Massachusetts in November 2013 and established a veterinary products division in 2015.